Anaphylactic reactions. Discontinue ongoing antibiotic use not directed against
Clostridium difficile if
Clostridium difficile-associated diarrhea (CDAD) is suspected or confirmed. Not for diabetic foot infections. Avoid in patients w/ known hypersensitivity to tetracycline-class antibacterials; as monotherapy in cIAI secondary to clinically apparent intestinal perforation. Consider cessation of treatment in cases suspected of developing pancreatitis. Acute pancreatitis; significant hepatic dysfunction & hepatic failure; hypofibrinogenemia; enamel hypoplasia; CDAD ranging from mild diarrhea to fatal colitis. Photosensitivity, pseudotumor cerebri & anti-anabolic action (leading to increased BUN, azotemia, acidosis & hyperphosphatemia). Monitor for evidence of worsening hepatic function & evaluate for risk/benefit of continuing therapy in patients who develop abnormal LFTs during therapy. Increase in all-cause mortality; risk of development of drug-resistant bacteria when used in absence of proven or strongly suspected bacterial infection; total bilirubin conc, prothrombin time & transaminases. Patients w/ ventilator-associated pneumonia. Obtain baseline blood coagulation parameters, including fibrinogen & continue to monitor regularly during treatment. Reserved for use in situations when alternative treatments are not suitable. May affect ability to drive & use machines. Severe hepatic impairment (Child Pugh C). Advise patients of potential risk to fetus if used during 2nd or 3rd trimester of pregnancy. May cause permanent discoloration of deciduous teeth (yellow-gray-brown) & reversible inhibition of bone growth when administered during 2nd & 3rd trimester of pregnancy, infancy & childhood to 8 yr. Lactation. Avoid use in ped patients. Ped patients w/ hepatic impairment. Decrease in fibula growth rate in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hr.
Sign Out
